The Effect of NAC in Decreasing the Incidence of Linezolid-induced Thrombocytopenia in Critically Ill Patients

Launched by HELWAN UNIVERSITY · Jul 6, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called acetylcysteine (NAC) may help reduce a side effect caused by another medication called linezolid, which can lower the number of platelets in the blood in critically ill patients. This condition, known as linezolid-induced thrombocytopenia (LIT), can be serious, so the study aims to see if acetylcysteine can help prevent this side effect or help patients recover their platelet levels more quickly if it does occur.

To participate in this study, individuals need to be at least 18 years old and currently admitted to the intensive care unit (ICU) where they are receiving linezolid treatment for at least one day. However, people who have certain blood disorders, are taking specific medications that affect blood cell production, or have had COVID-19 are not eligible to join. Participants in the trial will receive the study medication and be monitored closely to see how it affects their platelet levels and overall health. This trial is currently recruiting patients, and your involvement could help improve care for others facing similar health challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All adult patients, age \> or = 18 years old, admitted to the ICU with different indications.
• • Candidates for intravenous linezolid therapy for \> or =1 day.
• Exclusion Criteria:
• • Taking any myelosuppressive drug.
• • Baseline platelets \< 50000.
• • Patients with hematological malignancy.
• • COVID-19 patients.
• • Patients with immune thrombocytopenia.
• • Patients who refused to sign the informed consent